文献速递神经肿瘤

三级癌症中心治疗的高级别胶质瘤患者社会脆弱性与生存分析

Social vulnerability and survival among patients with high-grade glioma treated at a tertiary cancer center.
PubMed 文献 · J Neurooncol · 2026-07-30

研究纳入398例IDH野生型胶质母细胞瘤和62例IDH突变型4级星形细胞瘤成人患者,分析县级和普查区级社会脆弱性指数(SVI)与生存及治疗结局的关联。主要Cox模型未发现SVI与生存显著相关,但较高普查区级SVI与未行全切及未接受临床试验治疗的几率相关。

要点

  • 在达到三级神经肿瘤治疗的患者中,SVI与生存无显著关联。
  • 较高普查区级SVI与未行全切的几率增加相关(OR 1.19)。
  • 较高普查区级SVI与接受临床试验治疗的几率降低相关(OR 0.81)。

核心结论

  • 在达到三级神经肿瘤治疗的患者中,主要Cox模型未发现SVI与生存存在统计学显著关联。
  • 较高普查区级SVI与切除范围较小及接受临床试验治疗几率较低相关。

研究设计与样本

  • 回顾性队列研究,纳入2020至2025年在MD Anderson治疗且有PROACTIVE同意、生存随访和德克萨斯州居住数据的成人患者。
  • 采用2022年CDC/ATSDR SVI,按每增加0.1(10个百分位点)建模。
  • GBM主要Cox模型调整年龄、性别、体能状态、切除范围、MGMT甲基化、保险和距离。
  • 使用Grambsch-Therneau检验评估比例风险假设。

主要发现

  • GBM队列398例,IDH突变型4级星形细胞瘤队列62例。
  • GBM中,县级SVI与生存无关联(HR 1.00;95%CI 0.96-1.05;P=0.920)。
  • GBM中,休斯顿地区普查区级SVI与生存无关联(HR 1.05;95%CI 0.98-1.13;P=0.176)。
  • 探索性时变分析中,SVI与死亡关联随随访减弱(交互P=0.028)。
  • 较高普查区级SVI与未行全切几率增加相关(OR 1.19;95%CI 1.07-1.33;q=0.010),与临床试验治疗几率降低相关(OR 0.81;95%CI 0.71-0.92;q=0.008)。

临床怎么用

  • 对于已到达三级神经肿瘤中心的高级别胶质瘤患者,社会脆弱性对生存的影响可能有限。
  • 普查区级社会脆弱性较高者更可能未行全切且较少接受临床试验,需关注治疗可及性差异。

局限性

  • 研究为单中心回顾性设计,仅纳入有PROACTIVE同意和德克萨斯州居住数据的患者。
  • IDH突变型4级星形细胞瘤样本量较小(62例),分析为探索性。
  • SVI为区域层面指标,非个体层面社会经济地位测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We examined associations of county- and tract-level Social Vulnerability Index (SVI) with survival and treatment-related outcomes in adults with IDH-wildtype glioblastoma (GBM) or IDH-mutant grade 4 astrocytoma. METHODS: Adults treated at MD Anderson from 2020 to 2025 with PROACTIVE consent, survival follow-up, and Texas residential data were included. The 2022 CDC/ATSDR SVI was modeled per 0.1 increase (10 percentile points). Primary Cox models for GBM adjusted for age, sex, performance status, extent of resection, MGMT methylation, insurance, and distance. Proportional hazards were assessed using Grambsch-Therneau tests. RESULTS: Cohorts included 398 patients with GBM and 62 with IDH-mutant grade 4 astrocytoma. In GBM, SVI was not associated with survival in county-level analyses (HR per 0.1 increase, 1.00; 95% CI, 0.96-1.05; P = 0.920) or Houston-area tract-level analyses (HR, 1.05; 95% CI, 0.98-1.13; P = 0.176). In exploratory time-varying analysis, the SVI-mortality association attenuated over follow-up (interaction P = 0.028). Higher tract-level SVI was associated with greater odds of not undergoing gross-total resection (OR, 1.19; 95% CI, 1.07-1.33; q = 0.010) and lower odds of clinical-trial treatment (OR, 0.81; 95% CI, 0.71-0.92; q = 0.008). No significant survival association was identified in exploratory astrocytoma analyses. CONCLUSION: Among patients who reached tertiary neuro-oncology care, primary Cox models did not identify a statistically significant association between SVI and survival. Higher tract-level SVI was associated with less extensive resection and lower odds of clinical-trial treatment.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hsi AH, Wathoo C, Campbell E, et al. Social vulnerability and survival among patients with high-grade glioma treated at a tertiary cancer center. J Neurooncol. 2026. PMID: 42530702. doi:10.1007/s11060-026-05732-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。